PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

AOD-9604: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for AOD-9604 across studied indications.

Back to AOD-9604 overview

Research Summary

AOD-9604 has more completed human trials (6 trials, 900+ participants) than most peptides, but its pivotal Phase IIb trial failed to meet the primary weight loss endpoint. Early Phase II data showed modest weight loss (2.6-2.8 kg), but Novo Nordisk discontinued development. Safety was consistently good across all trials.

Evidence by Indication (2 indications)

Indication Tier Trials Summary
Weight loss / fat reduction Tier C 6 6 completed human trials (900+ participants) showed modest fat reduction but pivotal Phase IIb failed primary endpoint
Osteoarthritis Tier C 2 Early-phase trials suggest cartilage repair potential

Graded using our evidence tier methodology.

Citations (10 sources)

  1. 1. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Study

    (2015), Annals of clinical and laboratory science

  2. 2. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Study

    (2014), Journal of pharmaceutical and biomedical analysis

  3. 3. Current updates in the medical management of obesity. Study

    (2012), Recent patents on endocrine, metabolic & immune drug discovery

  4. 4. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Review

    (2007), Postepy higieny i medycyny doswiadczalnej (Online)

  5. 5. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Study

    (2006), Obesity (Silver Spring, Md.)

  6. 6. Obesity drugs in clinical development. Study

    (2006), Current opinion in investigational drugs (London, England : 2000)

  7. 7. Gateways to clinical trials. Clinical Trial

    (2005), Methods and findings in experimental and clinical pharmacology

  8. 8. Gateways to clinical trials. Clinical Trial

    (2003), Methods and findings in experimental and clinical pharmacology

  9. 9. Gateways to clinical trials. Clinical Trial

    (2003), Methods and findings in experimental and clinical pharmacology

  10. 10. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Study

    (2001), Endocrinology